Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: A report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

European Journal of Haematology

Volumn 90, Issue 5, 2013, Pages 355-364

  Park, Sophie ^a   Labopin, Myriam ^b   Yakoub Agha, Ibrahim ^c   Delaunay, Jacques ^d   Dhedin, Nathalie ^e   Deconinck, Eric ^f   Michallet, Mauricette ^g   Robin, Marie ^e   De Revel, Thierry ^h   Bernard, Marc ⁱ   Vey, Norbert ^j   Lioure, Bruno ^k   Lapusan, Simona ^l   Tabrizi, Reza ^m   Bourhis, Jean Henri ⁿ   Huynh, Anne ^o   Beguin, Yves ^p   Socié, Gérard ^e   Dreyfus, François ^a   Fenaux, Pierre ^q   Mohty, Mohamad ^d   more..

^a Université Paris V ^*  (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UAM Allogreffes de CSH   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g UNIVERSITÉ LYON 1   (France)

^h PERCY MILITARY HOSPITAL   (France)

ⁱ SERVICE DE RHUMATOLOGIE   (France)

^j Hopital Paoli Calmettes   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l Hematology   (France)

^m BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o UNIVERSITÉ DE TOULOUSE   (France)

^p UNIVERSITY OF LIÈGE   (Belgium)

^q UNIVERSITÉ PARIS 13   (France)

more..

Author keywords

Allotransplantation; Chronic myelomonocytic leukemia; Myelodysplastic; Splenomegaly

Indexed keywords

ANTHRACYCLINE; CYCLOSPORIN; CYTARABINE; HYDROXYUREA; INTERFERON; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELOMONOCYTIC LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84876706875     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12073     Document Type: Article

References (32)

1. Baudard M, Delmer A, Zittoun R. Chronic myelomonocytic leukemia in adults. Pathol Biol (Paris) 1997;45:605-11.
2. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 2006;47:417-23.
3. Elliott MA. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. Best Pract Res Clin Haematol 2006;19:571-93.
4. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 2004;3:218-26.
5. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417-24.
6. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-8.
7. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996;88:2480-7.
8. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011;29:1987-96.
9. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690-6.
10. Scott BL, Ramakrishnan A, Storer B, Becker PS, Petersdorf S, Estey EH, Deeg HJ. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010;148:944-7.
11. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008;32:587-91.
12. Zang DY, Deeg HJ, Gooley T, Anderson JE, Anasetti C, Sanders J, Myerson D, Storb R, Appelbaum F. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000;110:217-22.
13. Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011;17:908-15.
14. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, Myerson D, Appelbaum FR, Storb R, Deeg HJ. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005;11:713-20.
15. Krishnamurthy P, Lim ZY, Nagi W, Kenyon M, Mijovic A, Ireland R, Marsh J, Ho AY, Mufti GJ, Pagliuca A. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 2010;45:1502-7.
16. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, Niederwieser D, Zander AR, De Witte T. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002;118:67-73.
17. Elliott MA, Tefferi A, Hogan WJ, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006;37:1003-8.
18. Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S, Onida F, Beran M, Champlin RE, de Lima M. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004;33:1005-9.
19. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
21. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628-33.
22. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase II trial. Blood 2011;118:3824-31.
23. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-9.
24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
25. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007;40:381-7.
26. Ocheni S, Kroger N, Zabelina T, Zander AR, Bacher U. Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 2009;43:659-61.
27. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010;45:255-60.
28. Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012;97:393-401.
29. Droin N, Jacquel A, Hendra JB, et al. Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. Blood 2010;115:78-88.
30. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-83. doi:10.3324/haematol.2010.030957. Epub 2010 Nov 25.
31. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118:3932-41.
32. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151:365-75.